Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 16;82(18):3191-3197.
doi: 10.1158/0008-5472.CAN-22-1535.

BRCA1-Dependent and Independent Recruitment of PALB2-BRCA2-RAD51 in the DNA Damage Response and Cancer

Affiliations
Review

BRCA1-Dependent and Independent Recruitment of PALB2-BRCA2-RAD51 in the DNA Damage Response and Cancer

Tzeh Keong Foo et al. Cancer Res. .

Abstract

The BRCA1-PALB2-BRCA2 axis plays essential roles in the cellular response to DNA double-strand breaks (DSB), maintenance of genome integrity, and suppression of cancer development. Upon DNA damage, BRCA1 is recruited to DSBs, where it facilitates end resection and recruits PALB2 and its associated BRCA2 to load the central recombination enzyme RAD51 to initiate homologous recombination (HR) repair. In recent years, several BRCA1-independent mechanisms of PALB2 recruitment have also been reported. Collectively, these available data illustrate a series of hierarchical, context-dependent, and cooperating mechanisms of PALB2 recruitment that is critical for HR and therapy response either in the presence or absence of BRCA1. Here, we review these BRCA1-dependent and independent mechanisms and their importance in DSB repair, cancer development, and therapy. As BRCA1-mutant cancer cells regain HR function, for which PALB2 is generally required, and become resistant to targeted therapies, such as PARP inhibitors, targeting BRCA1-independent mechanisms of PALB2 recruitment represents a potential new avenue to improve treatment of BRCA1-mutant tumors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflicts of interest.

Figures

Figure 1.
Figure 1.
Domain structures of BRCA1, BARD1, PALB2 and BRCA2. Their key interacting partners involved in the DNA damage response are shown and their binding sites indicated. The triple lines between BRCA1 and BARD1 indicate a stoichiometric complex formation of the two proteins. NCP, nucleosome core particle.
Figure 2.
Figure 2.
HR initiation upon DSB formation and mechanisms of PALB2-BRCA2-RAD51 recruitment under different conditions. (A) Cartoon showing steps of HR initiation and the involvement of the relevant proteins in this review. (B-E) Cartoons showing PALB2-BRCA2 recruitment and the extent of RAD51 loading in cells with different BRCA1 and 53BP1 status. Panel B illustrates “canonical” PALB2 recruitment in normal cells by a direct interaction with BRCA1, with RNF168 serving as a stabilizing factor aside from its function as a histone E3 ligase; panel C depicts a blockade of PALB2 recruitment by 53BP1 and associated proteins in BRCA1 null cells; panel D shows recruitment of PALB2 through its interaction with RNF168 and the nucleosome core particle (via ChAM) in BRCA1/53BP1 double null cells; and panel E shows residual PALB2 recruitment by RNF168 in cells with disrupted PALB2-BRCA1 interaction. MRG15-mediated PALB2 tethering to actively transcribed chromatin regions (marked by H3K36me3) is also shown in B. A BRCA1 CC mutation affecting BRCA1-PALB2 interaction is indicated as a red dot in E. See text for details.

References

    1. Chen CC, Feng W, Lim PX, Kass EM, Jasin M. Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer. Annu Rev Cancer Biol 2018;2:313–36 - PMC - PubMed
    1. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006;22:719–29 - PubMed
    1. Tischkowitz M, Xia B. PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer research 2010;70:7353–9 - PMC - PubMed
    1. Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol 2020;38:674–85 - PMC - PubMed
    1. Niraj J, Farkkila A, D’Andrea AD. The Fanconi Anemia Pathway in Cancer. Annu Rev Cancer Biol 2019;3:457–78 - PMC - PubMed

Publication types

MeSH terms